论文部分内容阅读
目的 :比较常规护肝和支持疗法及联合应用肝复肽加大剂量胸腺肽对乙型亚重型肝炎的临床疗效。方法 :6 0例亚重型肝炎病例随机分为A、B两组 ,A组常规护肝支持疗法联合应用肝复肽加大剂量胸腺肽治疗 ,B组常规护肝和支持治疗。疗程均为 3个月。结果 :治疗 3个月后 ,临床症状消失率、肝功能复常率、HBsAg、HBeAg、HBV -DNA阴转率A组高于B组 ,病死率A组低于B组。结论 :在护肝支持疗法的基础上联合应用肝复肽加大剂量胸腺肽、治疗乙型亚重型肝炎能抑制乙肝病毒复制 ,减轻临床症状 ,更快改善肝功能 ,降低死亡率。
OBJECTIVE: To compare the clinical effects of conventional hepatoprotective and supportive therapy and the combination of hepatic recombination peptide and high dose of thymosin on sub-type B hepatitis B. Methods: Sixty cases of sub-severe hepatitis were randomly divided into A and B groups. Group A received conventional hepatic supportive therapy combined with hepatic recombination plus thymosin, while group B received conventional liver protection and supportive therapy. Treatment are 3 months. Results: After 3 months of treatment, the disappearance rate of clinical symptoms, the rate of abnormal liver function, HBsAg, HBeAg and HBV-DNA negative conversion rate in group A were higher than those in group B, and the mortality in group A was lower than that in group B. Conclusions: Combined application of hepatic recombination peptide and large dose of thymosin on the basis of hepatoprotective support can reduce the hepatitis B virus replication, alleviate the clinical symptoms, improve the liver function and reduce the mortality rate.